{"created":"2023-05-15T11:23:08.062287+00:00","id":2742,"links":{},"metadata":{"_buckets":{"deposit":"fdc8ca46-547b-4135-921a-32041dcf3f21"},"_deposit":{"created_by":1,"id":"2742","owners":[1],"pid":{"revision_id":0,"type":"depid","value":"2742"},"status":"published"},"_oai":{"id":"oai:showa.repo.nii.ac.jp:00002742","sets":["156:158:160:175"]},"author_link":["9497","9498"],"item_10006_alternative_title_1":{"attribute_name":"その他のタイトル","attribute_value_mlt":[{"subitem_alternative_title":"KRASおよびBRAF野生型、転移・再発結腸直腸癌に対する一次治療としてのFOLFOX療法もしくは、XELOX療法にCetuximabを併用した多施設共同第Ⅱ相試験（FLEET試験）"}]},"item_10006_date_granted_11":{"attribute_name":"学位授与年月日","attribute_value_mlt":[{"subitem_dategranted":"2018-03-20"}]},"item_10006_degree_grantor_9":{"attribute_name":"学位授与機関","attribute_value_mlt":[{"subitem_degreegrantor":[{"subitem_degreegrantor_name":"昭和大学"}],"subitem_degreegrantor_identifier":[{}]}]},"item_10006_degree_name_8":{"attribute_name":"学位名","attribute_value_mlt":[{"subitem_degreename":"博士(医学)"}]},"item_10006_description_10":{"attribute_name":"学位授与年度","attribute_value_mlt":[{"subitem_description":"2017年度"}]},"item_10006_dissertation_number_12":{"attribute_name":"学位授与番号","attribute_value_mlt":[{"subitem_dissertationnumber":"乙第3030号"}]},"item_10006_full_name_3":{"attribute_name":"著者(別名)","attribute_value_mlt":[{"nameIdentifiers":[{}],"names":[{"name":"SODA, Hitoshi"}]}]},"item_10006_relation_16":{"attribute_name":"他の資源との関係","attribute_value_mlt":[{"subitem_relation_name":[{"subitem_relation_name_text":"BMC Cancer 15:695, 2015"}]}]},"item_10006_select_23":{"attribute_name":"施設","attribute_value_mlt":[{"subitem_select_item":"藤が丘病院"}]},"item_10006_text_22":{"attribute_name":"学部講座部門","attribute_value_mlt":[{"subitem_text_value":"医/外科学講座/消化器・一般外科学部門"}]},"item_10006_version_type_18":{"attribute_name":"著者版フラグ","attribute_value_mlt":[{"subitem_version_type":"VoR"}]},"item_creator":{"attribute_name":"著者","attribute_type":"creator","attribute_value_mlt":[{"creatorNames":[{"creatorName":"曽田, 均"}],"nameIdentifiers":[{}]}]},"item_files":{"attribute_name":"ファイル情報","attribute_type":"file","attribute_value_mlt":[{"accessrole":"open_date","date":[{"dateType":"Available","dateValue":"2021-03-08"}],"displaytype":"detail","filename":"otsu3030_abstract.pdf","filesize":[{"value":"146.1 kB"}],"format":"application/pdf","licensetype":"license_note","mimetype":"application/pdf","url":{"label":"otsu3030_abstract","url":"https://showa.repo.nii.ac.jp/record/2742/files/otsu3030_abstract.pdf"},"version_id":"9d752ee7-90df-4895-9b40-098177259697"},{"accessrole":"open_date","date":[{"dateType":"Available","dateValue":"2020-08-24"}],"displaytype":"detail","filename":"otsu3030_fulltext.pdf","filesize":[{"value":"928.5 kB"}],"format":"application/pdf","licensetype":"license_note","mimetype":"application/pdf","url":{"label":"otsu3030_fulltext","url":"https://showa.repo.nii.ac.jp/record/2742/files/otsu3030_fulltext.pdf"},"version_id":"81913107-1833-4723-b0ad-83bd2a330c9a"},{"accessrole":"open_date","date":[{"dateType":"Available","dateValue":"2020-08-24"}],"displaytype":"detail","filename":"otsu3030_thesisreview.pdf","filesize":[{"value":"326.4 kB"}],"format":"application/pdf","licensetype":"license_note","mimetype":"application/pdf","url":{"label":"otsu3030_thesisreview","url":"https://showa.repo.nii.ac.jp/record/2742/files/otsu3030_thesisreview.pdf"},"version_id":"067cca93-9b79-457b-a543-f85cd58a96e9"}]},"item_language":{"attribute_name":"言語","attribute_value_mlt":[{"subitem_language":"eng"}]},"item_resource_type":{"attribute_name":"資源タイプ","attribute_value_mlt":[{"resourcetype":"doctoral thesis"}]},"item_title":"Multicenter Phase II study of FOLFOX or biweekly XELOX and Erbitux (cetuximab) as first-line therapy in patients with wild-type KRAS/BRAF metastatic colorectal cancer: The FLEET study","item_titles":{"attribute_name":"タイトル","attribute_value_mlt":[{"subitem_title":"Multicenter Phase II study of FOLFOX or biweekly XELOX and Erbitux (cetuximab) as first-line therapy in patients with wild-type KRAS/BRAF metastatic colorectal cancer: The FLEET study"}]},"item_type_id":"10006","owner":"1","path":["175"],"pubdate":{"attribute_name":"公開日","attribute_value":"2018-09-19"},"publish_date":"2018-09-19","publish_status":"0","recid":"2742","relation_version_is_last":true,"title":["Multicenter Phase II study of FOLFOX or biweekly XELOX and Erbitux (cetuximab) as first-line therapy in patients with wild-type KRAS/BRAF metastatic colorectal cancer: The FLEET study"],"weko_creator_id":"1","weko_shared_id":1},"updated":"2023-05-15T12:51:10.102575+00:00"}